Latest Insider Transactions at Arena Pharmaceuticals Inc (ARNA)
This section provides a real-time view of insider transactions for Arena Pharmaceuticals Inc (ARNA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARENA PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARENA PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2022
|
Robert Lisicki EVP, Chief Commercial Officer |
SELL
Other acquisition or disposition
|
Direct |
37,563
-49.61%
|
-
|
|
Mar 11
2022
|
Vincent Aurentz Executive VP and CBO |
SELL
Other acquisition or disposition
|
Direct |
55,964
-57.81%
|
-
|
|
Mar 11
2022
|
Joan Schmidt EVP, General Counsel & Sec |
SELL
Other acquisition or disposition
|
Direct |
36,287
-48.73%
|
-
|
|
Mar 11
2022
|
Amit Munshi President and CEO |
SELL
Other acquisition or disposition
|
Direct |
114,897
-41.78%
|
-
|
|
Mar 11
2022
|
Laurie Stelzer EVP & Chief Financial Officer |
SELL
Other acquisition or disposition
|
Direct |
37,208
-49.37%
|
-
|
|
Mar 11
2022
|
Douglas J. Manion EVP Research & Development |
SELL
Other acquisition or disposition
|
Direct |
36,462
-70.57%
|
-
|
|
Mar 11
2022
|
Nawal Ouzren Director |
SELL
Other acquisition or disposition
|
Direct |
4,555
-59.77%
|
-
|
|
Mar 11
2022
|
Jayson Donald Alexander Dallas Director |
SELL
Other acquisition or disposition
|
Direct |
7,152
-78.56%
|
-
|
|
Mar 11
2022
|
Steven J Schoch Director |
SELL
Other acquisition or disposition
|
Direct |
4,600
-100.0%
|
-
|
|
Mar 11
2022
|
Garry Arthur Neil Director |
SELL
Other acquisition or disposition
|
Direct |
11,217
-86.33%
|
-
|
|
Mar 11
2022
|
Jennifer Jarrett Director |
SELL
Other acquisition or disposition
|
Direct |
11,217
-86.33%
|
-
|
|
Mar 11
2022
|
Katharine Knobil Director |
SELL
Other acquisition or disposition
|
Direct |
6,821
-71.54%
|
-
|
|
Mar 11
2022
|
Kieran Gallahue Director |
SELL
Other acquisition or disposition
|
Direct |
9,283
-56.01%
|
-
|
|
Mar 11
2022
|
Kieran Gallahue Director |
SELL
Other acquisition or disposition
|
Indirect |
3,628
-100.0%
|
-
|
|
Mar 11
2022
|
Oliver Fetzer Director |
SELL
Other acquisition or disposition
|
Direct |
9,692
-57.87%
|
-
|
|
Mar 11
2022
|
Tina Susan Nova Director |
SELL
Other acquisition or disposition
|
Direct |
20,843
-92.64%
|
-
|
|
Mar 08
2022
|
Amit Munshi President and CEO |
SELL
Bona fide gift
|
Direct |
10,500
-8.37%
|
$1,029,000
$98.51 P/Share
|
|
Jan 03
2022
|
Vincent Aurentz Executive VP and CBO |
BUY
Grant, award, or other acquisition
|
Direct |
21,462
+28.02%
|
-
|
|
Jan 03
2022
|
Robert Lisicki EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,462
+36.36%
|
-
|
|
Jan 03
2022
|
Laurie Stelzer EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,462
+37.11%
|
-
|
|
Jan 03
2022
|
Amit Munshi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
85,847
+40.64%
|
-
|
|
Jan 03
2022
|
Douglas J. Manion EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
21,462
+37.05%
|
-
|
|
Jan 03
2022
|
Joan Schmidt EVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
21,462
+37.31%
|
-
|
|
Aug 16
2021
|
Amit Munshi President and CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+2.47%
|
$48,000
$48.19 P/Share
|
|
Aug 15
2021
|
Douglas J. Manion EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Aug 12
2021
|
Amit Munshi President and CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+2.53%
|
$50,000
$50.41 P/Share
|
|
Aug 10
2021
|
Amit Munshi President and CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+2.59%
|
$52,000
$52.91 P/Share
|
|
Aug 03
2021
|
Robert Lisicki EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,500
-29.58%
|
$1,050,000
$60.02 P/Share
|
|
Aug 03
2021
|
Robert Lisicki EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+34.25%
|
$700,000
$40.95 P/Share
|
|
Jun 15
2021
|
Jayson Donald Alexander Dallas Director |
SELL
Open market or private sale
|
Direct |
1,223
-14.6%
|
$80,718
$66.36 P/Share
|
|
Jun 11
2021
|
Garry Arthur Neil Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,067
+21.47%
|
-
|
|
Jun 11
2021
|
Steven J Schoch Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,600
+45.0%
|
-
|
|
Jun 11
2021
|
Jennifer Jarrett Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,067
+21.47%
|
-
|
|
Jun 11
2021
|
Tina Susan Nova Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,067
+13.51%
|
-
|
|
Jun 11
2021
|
Nawal Ouzren Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,067
+40.24%
|
-
|
|
Jun 11
2021
|
Oliver Fetzer Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,067
+24.04%
|
-
|
|
Jun 11
2021
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,067
+24.83%
|
-
|
|
Jun 11
2021
|
Jayson Donald Alexander Dallas Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,067
+26.8%
|
-
|
|
Jun 11
2021
|
Katharine Knobil Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,067
+31.02%
|
-
|
|
Mar 16
2021
|
Laurie Stelzer EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,356
-22.62%
|
$331,056
$76.1 P/Share
|
|
Mar 16
2021
|
Laurie Stelzer EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,600
+39.55%
|
-
|
|
Mar 15
2021
|
Joan Schmidt EVP, General Counsel & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
4,874
-25.03%
|
$375,298
$77.58 P/Share
|
|
Mar 15
2021
|
Joan Schmidt EVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
12,600
+39.28%
|
-
|
|
Mar 01
2021
|
Amit Munshi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
28,800
+44.07%
|
-
|
|
Mar 01
2021
|
Laurie Stelzer EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,660
+50.0%
|
-
|
|
Mar 01
2021
|
Vincent Aurentz Executive VP and CBO |
BUY
Grant, award, or other acquisition
|
Direct |
6,660
+16.52%
|
-
|
|
Mar 01
2021
|
Robert Lisicki EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,660
+29.26%
|
-
|
|
Mar 01
2021
|
Joan Schmidt EVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
6,660
+49.21%
|
-
|
|
Feb 16
2021
|
Vincent Aurentz Executive VP and CBO |
SELL
Open market or private sale
|
Direct |
2,524
-8.55%
|
$214,540
$85.0 P/Share
|
|
Feb 16
2021
|
Vincent Aurentz Executive VP and CBO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,524
+3.95%
|
$63,100
$25.1 P/Share
|